Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

CRBU

Caribou Biosciences, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1619856Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$11.0M
Net Income FY2025
$(148.0M)
EPS (Basic, as reported)
$-1.59
Net Margin FY2025
-1327.4%
ROE FY2025
-121.2%
Total Equity
$122.0M
Shares Out
107M
Business description

Caribou Biosciences, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 6 → 11 +10.6% CAGR
Fiscal yearFY2019FY2020FY2021⚑FY2022FY2023FY2024FY2025
Revenue6121014341011
Research & development(24)(34)(52)(82)(112)(130)(109)
General & administrative(16)(14)(24)(38)(38)(46)(38)
Total operating expenses(40)(48)(77)(120)(151)(177)(160)
Operating income(34)(36)(67)(106)(116)(167)(148)
Interest expense000————
Other income (expense), net300714180
Pre-tax income(31)(36)(67)(99)(102)(149)(149)
Income tax expense(8)(2)0000(1)
Net income(23)(34)(67)(99)(102)(149)(148)
EPS — basic——($2.11)($1.64)($1.38)($1.65)($1.59)
EPS — diluted——($2.11)($1.64)($1.38)($1.65)($1.59)
Shares outstanding — basic (M)——3261749093
Shares outstanding — diluted (M)——3261749093
  • ⚑ Weighted-average shares changed ×1.91 between FY2021 and FY2022 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.